We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

59 hedge funds and large institutions have $119M invested in Biotech Acquisition Company Unit in 2021 Q1 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
59
Holders Change
+59
Holders Change %
–
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
59
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$11.8M
2
HIM
HGC Investment Management
Ontario, Canada
+$11.3M
3
GCL
Glazer Capital LLC
New York
+$10.8M
4
BCM
BlueCrest Capital Management
Jersey
+$10.3M
5
LA
Linden Advisors
New York
+$6.98M

Top Sellers

No sellers this quarter

BIOTU Hedge Fund Activity: Q1 2021 in Review

59 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q1 2021, worth a combined $119M.

Buyers outnumbered sellers: 59 funds opened new BIOTU positions and 0 closed out — a net gain of 59 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $11.8M.

  • 59 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $119M of Biotech Acquisition Company Unit stock for Q1 2021.
  • 59 funds opened new Biotech Acquisition Company Unit positions in Q1 2021 and 0 closed out, a net change of +59 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q1 2021 was Aristeia Capital, an estimated $11.8M added.

Based on aggregated 13F filings for Q1 2021.